Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT03881761
What this trial is testing

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Who this might be right for
B-Cell Lymphoma Stage IRefractoryRelapsed
Henan Cancer Hospital 50
Testing effectiveness (Phase 2)Study completedNCT00936546
What this trial is testing

A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy

Who this might be right for
Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)
University Hospital, Ghent 3
Testing effectiveness (Phase 2)Study completedNCT00596804
What this trial is testing

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's LymphomaLymphoma, DiffuseLymphoma, Diffuse, Mixed Lymphocytic-Histiocytic
Gilead Sciences 39
Early research (Phase 1)Ended earlyNCT05292898
What this trial is testing

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Who this might be right for
Acute Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 10
Early research (Phase 1)Active Not RecruitingNCT01959698
What this trial is testing

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Who this might be right for
CD20 PositiveRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma+4 more
Roswell Park Cancer Institute 29
Testing effectiveness (Phase 2)Study completedNCT01998893
What this trial is testing

MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 38
Large-scale testing (Phase 3)Ended earlyNCT01659099
What this trial is testing

GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma CD20 Positive
The Lymphoma Academic Research Organisation 671
Early research (Phase 1)Active Not RecruitingNCT05424822
What this trial is testing

JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC 167
Early research (Phase 1)Ended earlyNCT04245722
What this trial is testing

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Who this might be right for
Lymphoma, B-CellChronic Lymphocytic Leukemia
Fate Therapeutics 98
Very early researchLooking for participantsNCT04283006
What this trial is testing

CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Relapsed and RefractoryLymphoid Hematological Malignancies
He Huang 100
Large-scale testing (Phase 3)UnknownNCT05040906
What this trial is testing

A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Who this might be right for
Recruiting
Shandong New Time Pharmaceutical Co., LTD 416
Not applicableUnknownNCT05768061
What this trial is testing

HBV Reactivation in Anti CD20 Treatment

Who this might be right for
Hepatitis B
HaEmek Medical Center, Israel 5,000
Early research (Phase 1)Looking for participantsNCT07100873
What this trial is testing

ADI-001 in Rheumatoid Arthritis

Who this might be right for
Rheumatoid Arthritis (RA)
Adicet Therapeutics 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT03688451
What this trial is testing

Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
Tahir Latif 20
Testing effectiveness (Phase 2)UnknownNCT03456466
What this trial is testing

Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma

Who this might be right for
Non-hodgkin's Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 122
Large-scale testing (Phase 3)Study completedNCT02867566
What this trial is testing

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Who this might be right for
Diffuse, Large B-Cell, Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 420
Early research (Phase 1)Study completedNCT04260932
What this trial is testing

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

Who this might be right for
B-cell Lymphoma
Hebei Yanda Ludaopei Hospital 12
Large-scale testing (Phase 3)Study completedNCT01649856
What this trial is testing

Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Hoffmann-La Roche 572
Early research (Phase 1)Ended earlyNCT04160195
What this trial is testing

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Who this might be right for
Lymphoma, B-CellLymphoma, Non-hodgkinsChronic Lymphocytic Leukemia+1 more
National Cancer Institute (NCI) 2
Testing effectiveness (Phase 2)Looking for participantsNCT05995054
What this trial is testing

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia

Who this might be right for
Immune ThrombocytopeniaTreatment
Institute of Hematology & Blood Diseases Hospital, China 110
Next Page